Orchard Therapeutics is focused on developing HSC gene therapy to address severe genetic diseases. The company's platform is designed to apply gene therapy to significant medical needs.

Orchard Therapeutics

Domain Not Resolving

HSTS

Amazon

Mobile Non Scaleable Content

DNSSEC

Amazon Virginia Region

CloudFront

Ruby on Rails Token

Squarespace Hosted

Envoy

Chief Business Officer

Adrien Lemoine

Chief Medical Officer and Co-Founder

Andrea Spezzi

Chief Development Officer (CDO)

Anne Dupraz

Chief Executive Officer

Bobby Gaspar

Sales and Support

Braden Parker

President & Chief Operating Officer

Frank Thomas

Chief Medical Officer

Leslie Meltzer

VP Clinical Development

Chris Dott

Vice President Program & Portfolio Managment and Chief of Staff

Chris Northey

James Geraghty

Simone Song

Jim Geraghty

Chief Medical Officer & Co-Founder

James Biggins

Vice President External Development and Supply

Nicoletta Loggia

Chief Technical Officer

Jason Bablak

Vice President, Regulatory Science, US

Ran Zheng

Companies that Went Public in 2018

Acquired Biotechnology Companies

Health Care Companies With More Than 50 Employees (Top 10K)

Health Diagnostics Acquired Companies With More Than 10 Employees

Orchard Therapeutics is a fully integrated commercial-stage company dedicated to treating the lives of patients with rare diseases through innovative gene therapies.

Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott-Aldrich syndrome), and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline.

The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.

RA Capital Management

Post-IPO Equity - Orchard Therapeutics

Deerfield Capital Management

Series C - Orchard Therapeutics

Baillie Gifford

F-Prime Capital

ORI Capital

Series B - Orchard Therapeutics

California Institute for Regenerative Medicine

Grant - Orchard Therapeutics

Series A - Orchard Therapeutics

London

England

United Kingdom

Europe

Orchard Therapeutics Announces Multiple Data Presentations and Publications

Orchard Therapeutics Celebrates Global Progress toward Advancing Newborn Screening for MLD on International ...

For every million-dollar gene therapy, Peter Marks gets an email from FDA chief Robert Califf

Pharming uproots angioedema gene therapy collab with Orchard

Orchard to lose out on milestone payments as Pharming Group ends collab

Pharming Group uproots angioedema gene therapy collab with Orchard

Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024

Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 ...

United States

North America

Canada

HTML5

Amazon Route 53

Microsoft Outlook

Google Compute Engine

Adobe Fonts

Google Tag Manager

Google Analytics

Google Fonts

Google Drive

Vimeo

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Orchard Therapeutics plc

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 18, 2024 4:58 AM	0df52172
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 18, 2024 4:58 AM	253e3015
crunchbase trigger	general	Oct 30, 2024 1:02 PM	4dd1a48e
crunchbase profile	general	Oct 31, 2024 7:57 AM	012e48da
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	51c541b5
peers	general	Oct 18, 2024 4:58 AM	406b7eb7
news basic	general	Oct 18, 2024 4:58 AM	59bf94ae
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ORCHARD-TX

Orchard Therapeutics

Last Close

16.65

23/01 21:00

Market Cap

380.11M

Beta: -

Volume Today

372.35K

Avg: -